Axa S.A. Alaunos Therapeutics, Inc. Transaction History

Axa S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $359,775 - $1.09 Million	-877,500 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$0.62 - $1.17 $544,050 - $1.03 Million	877,500 New	877,500 $570,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $956,475 - $1.66 Million	877,500 New	877,500 $956,000
Q3 2021 Nov 15, 2021	SELL	$1.44 - $2.73 $86,832 - $164,619	-60,300 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$2.63 - $3.67 $158,589 - $221,301	60,300 New	60,300 $159,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.